

## DAFTAR PUSTAKA

Aebi, S., Davidson, T., Gruber, G. and Castiglione, M. (2010) 'Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up', *Ann Oncol*, 21 Suppl 5, pp. v9-14. Available at: 10.1093/annonc/mdq159

Aebi, S., Karlsson, P. and Wapnir, I.L. (2022) 'Locally advanced breast cancer', *Breast*, 62 Suppl 1(Suppl 1), pp. S58-s62. Available at: 10.1016/j.breast.2021.12.011

Amin, M.B., Greene, F.L., Edge, S.B., Compton, C.C., Gershenwald, J.E., Brookland, R.K., Meyer, L., Gress, D.M., Byrd, D.R. and Winchester, D.P. (2017) 'The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging', *CA Cancer J Clin*, 67(2), pp. 93-99. Available at: 10.3322/caac.21388

Blanda, V., Bracale, U.M., Di Taranto, M.D. and Fortunato, G. (2020) 'Galectin-3 in Cardiovascular Diseases', *Int J Mol Sci*, 21(23) Available at: 10.3390/ijms21239232

Boutas I, Kontomanolis EN and Z., F. (2021) 'Galectin-3 as a marker of breast cancer: A systematic review', *Mol Biol Rep*, (48), pp. 1479–1491.

Boutas, I., Potiris, A., Makrakis, E., Messaropoulos, P., Papaioannou, G.K. and Kalantaridou, S. (2021) 'The expression of Galectin-3 in breast cancer and its association with metastatic disease: a systematic review of the literature', *Mol Biol Rep*, 48(1), pp. 807-815. Available at: 10.1007/s11033-020-06122-x

Cho, J.H., Park, J.M., Park, H.S., Park, S., Kim, S.I. and Park, B.W. (2013) 'Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer', *J Surg Oncol*, 108(8), pp. 531-6. Available at: 10.1002/jso.23439

Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009) 'New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)', *Eur J Cancer*, 45(2), pp. 228-47. Available at: 10.1016/j.ejca.2008.10.026

Ellingson, B.M., Wen, P.Y., Chang, S.M., van den Bent, M., Vogelbaum, M.A., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A.B., Gilbert, M.R., de Groot, J.F., Weller, M., Galanis, E. and Cloughesy, T.F. (2023) 'Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival', *Neuro Oncol*, 25(6), pp. 1017-1028. Available at: 10.1093/neuonc/noad002

Elsayed, B., Alksas, A., Shehata, M., Mahmoud, A., Zaky, M., Alghandour, R., Abdelwahab, K., Abdelkhalek, M., Ghazal, M., Contractor, S., El-Din Moustafa, H. and El-Baz, A. (2023) 'Exploring Neoadjuvant Chemotherapy, Predictive Models, Radiomic, and Pathological Markers in Breast Cancer: A Comprehensive Review', *Cancers (Basel)*, 15(21) Available at: 10.3390/cancers15215288

Engstrøm, M.J., Opdahl, S., Hagen, A.I., Romundstad, P.R., Akslen, L.A., Haugen, O.A., Vatten, L.J. and Bofin, A.M. (2013) 'Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients', *Breast Cancer Res Treat*, 140(3), pp. 463-73. Available at: 10.1007/s10549-013-2647-2

Febriani, A., Pujiastuti, F. and Teodhora, T. (2024) 'Characteristics of Chemotherapy Treatments for Breast Cancer Patients at Bhayangkara Tk.1 Pudsokkes Polri Hospital, Jakarta', *Indonesian Journal of Cancer; Vol 18, No 3 (2024): September* DO - 10.33371/ijoc.v18i3.1131. Available at: <https://indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/1131>.

Ferlay, J., Laversanne, M., Ervik, M., Lam, F., , Colombet, M., Mery, L., Piñeros, M., Znaor, A. and Soerjomataram, I., Bray, F (2024) 'Global Cancer Observatory: Cancer Tomorrow', *International Agency for Research on Cancer 2024*. Available at: <https://gco.iarc.fr/tomorrow>.

Grisold, W., Cavaletti, G. and Windebank, A.J. (2012) 'Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention', *Neuro Oncol*, 14 Suppl 4(Suppl 4), pp. iv45-54. Available at: 10.1093/neuonc/nos203

Hayden, M.S. and Ghosh, S. (2008) 'Shared principles in NF-kappaB signaling', *Cell*, 132(3), pp. 344-62. Available at: 10.1016/j.cell.2008.01.020

Ilmer, M., Mazurek, N., Gilcrease, M.Z., Byrd, J.C., Woodward, W.A., Buchholz, T.A., Acklin, K., Ramirez, K., Hafley, M., Alt, E., Vykoukal, J. and Bresalier, R.S. (2016) 'Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells', *Breast Cancer Res*, 18(1), p. 97. Available at: 10.1186/s13058-016-0757-6

Johannes, L., Jacob, R. and Leffler, H. (2018) 'Galectins at a glance', *J Cell Sci*, 131(9) Available at: 10.1242/jcs.208884

Jordan, M.A. and Wilson, L. (2004) 'Microtubules as a target for anticancer drugs', *Nat Rev Cancer*, 4(4), pp. 253-65. Available at: 10.1038/nrc1317

Kaufmann, M., von Minckwitz, G., Mamounas, E.P., Cameron, D., Carey, L.A., Cristofanilli, M., Denkert, C., Eiermann, W., Gnant, M., Harris, J.R., Karn, T., Liedtke, C., Mauri, D.,

Rouzier, R., Ruckhaeberle, E., Semiglazov, V., Symmans, W.F., Tutt, A. and Pusztai, L. (2012) 'Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer', *Ann Surg Oncol*, 19(5), pp. 1508-16. Available at: 10.1245/s10434-011-2108-2

Kavallaris, M. (2010) 'Microtubules and resistance to tubulin-binding agents', *Nat Rev Cancer*, 10(3), pp. 194-204. Available at: 10.1038/nrc2803

Ko, F.C.F., Yan, S., Lee, K.W., Lam, S.K. and Ho, J.C.M. (2023) 'Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy', *Biomolecules*, 13(6) Available at: 10.3390/biom13060902

Lainetti, P.d.F., Leis-Filho, A.F., Laufer-Amorim, R., Battazza, A. and Fonseca-Alves, C.E. (2020) 'Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems', *Pharmaceutics*, 12(12), p. 1193. Available at: <https://www.mdpi.com/1999-4923/12/12/1193>.

Liu, F.T. and Rabinovich, G.A. (2005) 'Galectins as modulators of tumour progression', *Nat Rev Cancer*, 5(1), pp. 29-41. Available at: 10.1038/nrc1527

Mahvi, D.A., Liu, R., Grinstaff, M.W., Colson, Y.L. and Raut, C.P. (2018) 'Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies', *CA Cancer J Clin*, 68(6), pp. 488-505. Available at: 10.3322/caac.21498

Mani, S., Chen, Y., Li, X., Arlinghaus, L., Chakravarthy, A.B., Abramson, V., Bhave, S.R., Levy, M.A., Xu, H. and Yankeelov, T.E. (2013) 'Machine learning for predicting the response of breast cancer to neoadjuvant chemotherapy', *J Am Med Inform Assoc*, 20(4), pp. 688-95. Available at: 10.1136/amiajnl-2012-001332

Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. (2004) 'Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity', *Pharmacol Rev*, 56(2), pp. 185-229. Available at: 10.1124/pr.56.2.6

Nabi, I.R., Shankar, J. and Dennis, J.W. (2015) 'The galectin lattice at a glance', *J Cell Sci*, 128(13), pp. 2213-9. Available at: 10.1242/jcs.151159

Niang, D., Ka, S., Hendricks, J., Diouf, D., Gaba, F., Diouf, A., Diop, M., Mbow, M., Faye, B., Diallo, R., Niang, M., Deme, A., Mbengue, B. and Dieye, A. (2022a) 'Profile of plasma galectin-3 concentrations in breast cancer patients receiving chemotherapy', *Open J Pathol*, 12((1)), pp. 22-33.

Niang, D., ka, S., Hendricks, J., Diouf, D., Gaba, F., Diouf, A., Diop, M., Mbow, M., Faye, B., Ndiaye, R., Niang, M., Deme, A., Mbengue, B. and Dieye, A. (2022b) 'Profile of Plasma Galectin-3 Concentrations, Inflammatory Cytokines Levels and Lymphocytes Status in

Breast Cancer under Chemotherapy', *Open Journal of Immunology*, 12, pp. 1-14.  
Available at: 10.4236/oji.2022.121001

Ochieng, J., Furtak, V. and Lukyanov, P. (2002) 'Extracellular functions of galectin-3', *Glycoconj J*, 19(7-9), pp. 527-35. Available at: 10.1023/B:GLYC.0000014082.99675.2f

See, S.H.C. and Siziopikou, K.P. (2022) 'Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges', *Pathol Res Pract*, 230, p. 153753. Available at: 10.1016/j.prp.2021.153753

Shafiq, A., Moore, J., Suleman, A., Faiz, S., Farooq, O., Arshad, A., Tehseen, M., Zafar, A., Ali, S.H., Din, N.U., Loya, A., Siddiqui, N. and Rehman, F.K. (2020) 'Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study', *Int J Breast Cancer*, 2020, p. 4824813. Available at: 10.1155/2020/4824813

Shatz-Azoulay, H., Vinik, Y., Isaac, R., Kohler, U., Lev, S. and Zick, Y. (2020) 'The Animal Lectin Galectin-8 Promotes Cytokine Expression and Metastatic Tumor Growth in Mice', *Scientific Reports*, 10.

Song, L., Tang, J.-w., Owusu, L., Sun, M.-Z., Wu, J. and Zhang, J. (2014) 'Galectin-3 in cancer', *Clinica Chimica Acta*, 431, pp. 185-191. Available at:  
<https://doi.org/10.1016/j.cca.2014.01.019>

Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., Desmedt, C., Larsimont, D., Cardoso, F., Peterse, H., Nuyten, D., Buyse, M., Van de Vijver, M.J., Bergh, J., Piccart, M. and Delorenzi, M. (2006) 'Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis', *J Natl Cancer Inst*, 98(4), pp. 262-72. Available at: 10.1093/jnci/djj052

Steenbruggen, T.G., van Ramshorst, M.S., Kok, M., Linn, S.C., Smorenburg, C.H. and Sonke, G.S. (2017) 'Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies', *Drugs*, 77(12), pp. 1313-1336. Available at: 10.1007/s40265-017-0774-5

Tsang, J.Y.S. and Tse, G.M. (2020) 'Molecular Classification of Breast Cancer', *Adv Anat Pathol*, 27(1), pp. 27-35. Available at: 10.1097/pap.0000000000000232

Villacampa, G., Matikas, A., Oliveira, M., Prat, A., Pascual, T. and Papakonstantinou, A. (2023) 'Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis', *Eur J Cancer*, 190, p. 112885. Available at: 10.1016/j.ejca.2023.03.042

Wang, Y.H., Chen, C.Y., Liu, N.Y., Chang, C.-S. and Hung, C.-C. (2018) 'Impact of ABCB1 genetic polymorphisms on the interactions between novel dipyrone derivatives and P-glycoprotein', *The FASEB Journal*, 31 Available at: 10.1096/fasebj.31.1\_supplement.1064.4

Xin, Y., Shen, G., Zheng, Y., Guan, Y., Huo, X., Li, J., Ren, D., Zhao, F., Liu, Z., Li, Z. and Zhao, J. (2021) 'Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis', *BMC Cancer*, 21(1), p. 1261. Available at: 10.1186/s12885-021-08997-w

Yang, R.Y., Rabinovich, G.A. and Liu, F.T. (2008) 'Galectins: structure, function and therapeutic potential', *Expert Rev Mol Med*, 10, p. e17. Available at: 10.1017/s1462399408000719

Zheng, P., Xiao, Y., Wu, Z., Wang, Q., Lv, Y., Niu, W., Zhang, Y., Xiao, J., Cao, J., Li, M., Lei, P. and Huang, T. (2025) 'Tumor-secreted galectin-3 suppresses antitumor response by inducing IL-10(+) B cells', *J Immunother Cancer*, 13(5) Available at: 10.1136/jitc-2024-011445

No	Nama	Usia	Status menopause	Grade histologi	Respon kemoterapi	Hormon receptor	Status HER2	IHC Galectin 3
1	Marhati	51	pre menopause	3	stable	negatif	negatif	3
2	Hj. Hasniar	46	pre menopause	3	stable	negatif	positif	3
3	Rosdiana	42	Pre menopause	3	stable	negatif	negatif	0
4	Suriani	39	pre menopause	2	partial	positif	negatif	0
5	Harnengsih	41	pre menopause	3	stable	negatif	negatif	3
6	Enny Triana	46	pre menopause	3	partial	positif	negatif	1
7	Nasriah	52	post menopause	2	stable	negatif	positif	3
8	Darwiah	55	post menopause	2	partial	positif	positif	1
9	Aminah	46	pre menopause	3	partial	positif	positif	1
10	Rugayah	56	post menopause	3	stable	positif	positif	0
11	Hasrati Ramli	55	post menopause	3	stable	positif	positif	2
12	Indriyani Madjid	49	pre menopause	2	partial	positif	positif	1
13	YATINI	68	post menopause	3	stable	positif	negatif	3
14	Martini	50	post menopause	2	partial	positif	negatif	0
15	Sakka	59	post menopause	3	stable	negatif	negatif	2

16	Andi punna	55	post menopause	2	stable	negatif	positif	3
17	Gustini	44	pre menopause	3	partial	negatif	negatif	1
18	Hasna	50	post menopause	1	partial	positif	negatif	0
19	Andi heriati	51	pre menopause	3	stable	negatif	positif	3
20	NAHARIA	54	post menopause	2	stable	positif	negatif	3
21	REVA F TANJUNG	20	pre menopause	1	partial	positif	negatif	0
22	SUMIATI	53	post menopause	1	partial	positif	positif	1
23	IRMAYANI	46	pre menopause	3	stable	negatif	positif	3
24	ANDI SUHAENI	59	post menopause	3	stable	negatif	positif	1
25	BASSE	65	post menopause	2	stable	negatif	negatif	0
26	A.RAMLAH BUDY	56	post menopause	1	partial	positif	negatif	1
27	WAODE HATIMA	47	pre menopause	1	partial	positif	positif	2
28	FATMAWATI	53	post menopause	3	stable	positif	negatif	2
29	NURMAWATI	40	pre menopause	2	stgable	positif	positif	1
30	yatini	69	post menopause	3	partial	positif	negatif	2
31	wisdawati	39	pre menopause	1	partial	positif	negatif	1
32	june	50	post menopause	1	partial	positif	negatif	3
33	Marwah	55	pre menopause	1	partial	positif	negatif	2
34	Raoda	39	pre menopause	3	stable	positif	positif	0
35	hamida	52	post menopause	2	partial	negatif	positif	0
36	maheria	49	pre menopause	1	stable	negatif	negatif	1
37	muliati	56	post menopause	3	stable	positif	negatif	2
38	ANDI ERNAWATI	62	post menopause	3	stable	positif	negatif	3
39	Hadera	55	post menopause	2	partial	positif	positif	1
40	Sumiati	50	post menopause	3	minimal	positif	negatif	2
41	Yuniarti	52	post menopause	1	partial	negatif	positif	1
42	Bua Suppe	70	post menopause	2	minimal	negatif	positif	3
43	Hania	49	pre menopause	3	partial	positif	positif	0
44	Aggreini Roosye	48	pre menopause	1	partial	positif	negatif	1
45	Ismiati	48	pre menopause	3	stable	positif	positif	3
46	Sitti Nur	61	post menopause	2	stable	negatif	negatif	1
47	Farida	49	pre menopause	2	partial	positif	negatif	1
48	Aminah	47	pre menopause	2	partial	positif	positif	1
49	Nurung	46	pre menopause	2	partial	positif	positif	0
50	Rappe	37	pre menopause	3	stable	positif	positif	2
51	Serfin	62	post menopause	3	stable	positif	positif	3
52	Masita	42	pre menopause	2	stable	negatif	negatif	3
53	Andi Farwanti	48	pre menopause	2	partial	positif	negatif	0
54	Iin Fitriani	42	pre menopause	1	complete	positif	positif	0

